MYC.md
... ...
@@ -23,10 +23,10 @@ timeline
23 23
24 24
|Entity|Tier|Description |
25 25
|:------:|:----:|--------------------------------------|
26
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021b]|
26
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021]|
27 27
|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
28 28
|![BL](images/icons/BL_tier1.png) |1-a | aSHM target and high-confidence BL gene [@johnstonCmycHypermutationBurkitt1992]|
29
-|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene [@pasqualucciHypermutationMultipleProtooncogenes2001a]|
29
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene [@pasqualucciHypermutationMultipleProtooncogenes2001]|
30 30
|![FL](images/icons/FL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous |
31 31
32 32
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
MYCBP2.md
... ...
@@ -19,7 +19,7 @@ timeline
19 19
20 20
|Entity|Tier|Description |
21 21
|:------:|:----:|--------------------------------------|
22
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021b]|
22
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
23 23
24 24
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 25
NANOG.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|-----------------------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018b]|
20
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
NFKBIA.md
... ...
@@ -22,9 +22,9 @@ timeline
22 22
23 23
|Entity|Tier|Description |
24 24
|:------:|:----:|--------------------------------------|
25
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@wienandGenomicAnalysesFlowsorted2019b]|
25
+|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@wienandGenomicAnalysesFlowsorted2019]|
26 26
|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lakeMutationsNFKBIAEncoding2009]|
27
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023b]|
27
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
28 28
29 29
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
30 30